Latest news with #SingularitySapiensMouse
Business Wire
6 days ago
- Business
- Business Wire
Leveragen and Propeller Bio Announce Strategic Collaboration to Advance Antibody and Protein Therapeutics
BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Leveragen, a Boston-based biotechnology company pioneering next-generation in vivo antibody discovery platforms, announced today a strategic collaboration with Propeller Bio, a newly launched biotechnology company focused on antibody and protein-based therapeutics. As part of the partnership, Propeller Bio will support the continued development of Leveragen's antibody discovery platforms through a strategic investment. In turn, Propeller will collaborate closely with Leveragen and gain access to Leveragen's full suite of proprietary antibody mouse models, including the Singularity Sapiens Mouse, the industry-leading fully human single-domain antibody discovery platform. 'Leveragen's Singularity Sapiens Mouse is a differentiated platform for antibody discovery, It provides a unique option for high-quality, in vivo matured human VH domains with impressive diversity and developability." - Dr. David Shen, CEO of Propeller Bio Share The Singularity Sapiens Mouse is engineered to produce robust immune responses across a broad range of antigens, enabling efficient discovery of fully human VH-only antibodies with strong developability and diverse epitope coverage. The platform supports multiple therapeutic formats, including bispecifics, antibody-drug conjugates, CAR-T therapies, and mRNA-encoded antibodies, making it a versatile tool for biologics development. 'We're excited to collaborate with Dr. David Shen and the team at Propeller Bio,' said Weisheng Chen, PhD, Founder and CEO of Leveragen. 'David has a remarkable track record of bringing innovative biomedicines to patients in need. We believe Propeller Bio is well positioned to lead the next wave of therapeutic breakthroughs, and we're proud to support their work with our cutting-edge antibody discovery platforms.' David W. Shen, PhD, Founder and CEO of Propeller Bio, is a widely recognized leader in antibody and protein therapeutics. He previously held senior leadership roles at Amgen, Merck, Teva, and NGM Bio. Most recently, he was Founder and CEO of Proteologix, a leader in the development of bispecific antibodies for immune-mediated diseases. In less than three years since inception, the company was acquired by Johnson & Johnson for $850 million upfront and an undisclosed milestone payment in 2024. 'Leveragen's Singularity Sapiens Mouse is a differentiated platform for antibody discovery,' said Dr. Shen. 'It provides a unique option for high-quality, in vivo matured human VH domains with impressive diversity and developability. This platform presents a compelling alternative to camelid immunization or synthetic libraries, offering speed, flexibility, and translational relevance. It gives us a solid foundation for building a differentiated pipeline.' This collaboration highlights Leveragen's growing role as a trusted discovery partner for biotech companies pushing the frontiers of biologics innovation. About Leveragen Leveragen is a biotech company based in Woburn, Massachusetts, focused on accelerating biologics innovation through next-generation in vivo discovery platforms. Its Singularity Suite includes a collection of genetically engineered mouse models capable of generating exclusively single-domain antibodies from the VH repertoires of humans, mice, and companion animals. These platforms support the development of advanced therapeutic modalities, including bispecifics, ADCs, mRNA-encoded antibodies, targeted drug delivery, and cell therapies. Leveragen's technologies are trusted by leading biotech and pharmaceutical companies around the world. LinkedIn About Propeller Bio Propeller Bio is founded by David Shen along with a group of seasoned biotech entrepreneurs with a proven track record of success. Supported by leading investors, the company focuses on discovering and developing innovative biologic therapeutics designed to safely and effectively target multiple disease-driving pathways, aiming for synergistic effects to treat patients with unmet medical needs. The organization boasts a diverse team with extensive expertise in drug discovery and development, and is based in the Bay Area, California.
Associated Press
29-01-2025
- Business
- Associated Press
Leveragen Announces Strategic Collaboration with Moonlight Bio to Advance T Cell Therapies Using Proprietary Fully Human Single-Domain Antibody Technology
WOBURN, Mass.--(BUSINESS WIRE)--Jan 29, 2025-- Leveragen Inc., a Boston-based biotech company specializing in next-generation genetic models for antibody discovery, today announced a strategic collaboration with Moonlight Bio, a Seattle-based biotech company pioneering advanced T cell therapies. This partnership aims to develop cutting-edge T cell therapies to address some of the most challenging and difficult-to-treat cancers. This press release features multimedia. View the full release here: Leveragen Announces Strategic Collaboration with Moonlight Bio to Advance T Cell Therapies. The collaboration integrates Leveragen's proprietary Singularity Sapiens Mouse platform, a groundbreaking tool for generating fully human single-domain antibodies, with Moonlight Bio's expertise in T cell engineering. Together, the two companies seek to create T cell therapies with enhanced functionality, persistence, and efficacy, overcoming significant barriers in the treatment of solid tumors. (Graphic: Business Wire) The collaboration integrates Leveragen's proprietary Singularity Sapiens Mouse platform, a groundbreaking tool for generating fully human single-domain antibodies, with Moonlight Bio's expertise in T cell engineering. Together, the two companies seek to create T cell therapies with enhanced functionality, persistence, and efficacy, overcoming significant barriers in the treatment of solid tumors. 'Leveragen's mission is to drive innovation in the fight against life-threatening diseases, and expanding our fully human single-domain antibody technology into transformative T cell therapies aligns seamlessly with this vision,' said Weisheng Chen, Founder and CEO of Leveragen. 'Through this partnership with Moonlight Bio, we are combining our state-of-the-art antibody discovery platform with their advanced cell engineering capabilities to develop T cell therapies that have the potential to make a meaningful difference for patients.' 'At Moonlight Bio, we are dedicated to delivering T cell therapies that break through barriers obstructing successful outcomes in solid tumors – the vast majority of the global cancer disease burden,' said Jordan Jarjour, Moonlight Bio's CSO. 'Leveragen's Singularity Sapiens Mouse platform is a powerful tool for generating fully human single-domain antibodies with properties that could optimally translate into advanced T cell therapies, particularly when combined with the tools and technologies that the Moonlight Bio team is advancing. We are very excited to collaborate with Leveragen as we explore and create new solutions in this space.' Under the terms of the agreement, Leveragen will spearhead the discovery of fully human single-domain antibodies against therapeutic targets and Moonlight Bio will oversee the preclinical development of T cell therapies. This collaboration highlights Leveragen's leadership in single-domain antibody discovery and its commitment to advancing immunotherapy through innovative science and transformative applications. About Leveragen Leveragen is a genetic engineering company at the forefront of developing next-generation models for antibody discovery and biologics innovation. Leveragen's flagship platform, the Singularity Sapiens Mouse, is designed to produce heavy chain-only antibodies from the entire human VH repertoire precisely integrated into the mouse genome. By eliminating conventional antibody interference and faithfully replicating human immunoglobulin gene expression, the platform optimizes B cell development and generates robust immune responses, enabling the efficient derivation of fully human single-domain antibodies with unsurpassed diversity, affinity, and developability. This proprietary platform accelerates the discovery and development of diverse therapeutic modalities, including bispecifics, ADCs, CAR T, and mRNA-based treatments. Headquartered in Woburn, Massachusetts, Leveragen collaborates with global pharmaceutical and biotechnology leaders to drive next-generation therapeutic development. For more information, visit About Moonlight Bio Moonlight Bio, Inc. is a preclinical-stage biotechnology company based in Seattle, WA aiming to develop potency enhanced T cell therapies that provide new hope for patients suffering from cancer. Moonlight's core technologies were illuminated by nature itself and are designed to confront the disappointing reality that therapies for solid tumors are simply not potent enough to generate the deep and durable responses that patients urgently need. To learn more, connect with Moonlight Bio on LinkedIn and visit us at SOURCE: Leveragen Inc. Copyright Business Wire 2025. PUB: 01/29/2025 08:08 AM/DISC: 01/29/2025 08:08 AM
